1. Home
  2. MELI vs VRTX Comparison

MELI vs VRTX Comparison

Compare MELI & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MercadoLibre Inc.

MELI

MercadoLibre Inc.

HOLD

Current Price

$1,955.75

Market Cap

95.0B

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$549.51

Market Cap

123.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MELI
VRTX
Founded
1999
1989
Country
Uruguay
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
EDP Services
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
95.0B
123.4B
IPO Year
2007
2006

Fundamental Metrics

Financial Performance
Metric
MELI
VRTX
Price
$1,955.75
$549.51
Analyst Decision
Strong Buy
Buy
Analyst Count
17
29
Target Price
$2,666.47
$539.69
AVG Volume (30 Days)
484.7K
1.2M
Earning Date
05-04-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
4.54
836.54
EPS
17.42
8.33
Revenue
$28,893,000,000.00
$2,488,652,000.00
Revenue This Year
$36.23
$10.79
Revenue Next Year
$24.20
$10.47
P/E Ratio
$114.64
$66.37
Revenue Growth
39.06
46.20
52 Week Low
$1,495.00
$374.17
52 Week High
$2,548.50
$555.69

Technical Indicators

Market Signals
Indicator
MELI
VRTX
Relative Strength Index (RSI) 64.93 66.66
Support Level $1,929.10 $458.05
Resistance Level $2,128.30 N/A
Average True Range (ATR) 65.94 13.59
MACD 12.80 3.33
Stochastic Oscillator 95.56 92.42

Price Performance

Historical Comparison
MELI
VRTX

About MELI MercadoLibre Inc.

MercadoLibre is the largest e-commerce marketplace in Latin America, with more than 120 million unique active buyers and 1 million active sellers at the end of 2025. The company is roughly split between its e-commerce business, which includes its fulfillment and advertising services, and its fintech segment, which comprises its rapidly expanding payment and digital wallet platform (Mercado Pago) and its lending business (Mercado Credito). While the company operates in 18 countries, its primary markets are Brazil, Argentina, and Mexico, which account for more than 95% of its revenue.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: